Truvestments Capital LLC Acquires 155 Shares of Charles River Laboratories International, Inc. (NYSE:CRL)

Truvestments Capital LLC increased its holdings in Charles River Laboratories International, Inc. (NYSE:CRL) by 6.4% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 2,562 shares of the medical research company’s stock after purchasing an additional 155 shares during the quarter. Truvestments Capital LLC’s holdings in Charles River Laboratories International were worth $473,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other large investors also recently modified their holdings of CRL. Wellington Management Group LLP grew its stake in shares of Charles River Laboratories International by 135,927.9% in the third quarter. Wellington Management Group LLP now owns 3,740,768 shares of the medical research company’s stock worth $736,819,000 after purchasing an additional 3,738,018 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of Charles River Laboratories International in the fourth quarter worth about $42,776,000. Cooke & Bieler LP grew its stake in shares of Charles River Laboratories International by 42.1% in the fourth quarter. Cooke & Bieler LP now owns 426,767 shares of the medical research company’s stock worth $78,781,000 after purchasing an additional 126,372 shares during the last quarter. Mizuho Securities USA LLC grew its stake in shares of Charles River Laboratories International by 2,336.4% in the third quarter. Mizuho Securities USA LLC now owns 96,871 shares of the medical research company’s stock worth $19,081,000 after purchasing an additional 92,895 shares during the last quarter. Finally, Premier Fund Managers Ltd grew its stake in shares of Charles River Laboratories International by 56.3% in the third quarter. Premier Fund Managers Ltd now owns 250,000 shares of the medical research company’s stock worth $49,573,000 after purchasing an additional 90,000 shares during the last quarter. 98.91% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research firms have weighed in on CRL. William Blair cut Charles River Laboratories International from an “outperform” rating to a “market perform” rating in a research report on Wednesday, January 22nd. Robert W. Baird cut their price objective on Charles River Laboratories International from $177.00 to $173.00 and set a “neutral” rating on the stock in a research report on Thursday, February 20th. CLSA cut Charles River Laboratories International from a “hold” rating to an “underperform” rating and set a $164.00 price objective on the stock. in a research report on Monday, November 18th. Barclays cut their price objective on Charles River Laboratories International from $205.00 to $166.00 and set an “equal weight” rating on the stock in a research report on Tuesday, February 18th. Finally, Redburn Atlantic raised Charles River Laboratories International from a “sell” rating to a “neutral” rating and set a $188.00 price objective on the stock in a research report on Monday, March 3rd. One analyst has rated the stock with a sell rating, fifteen have assigned a hold rating and one has assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $198.36.

Charles River Laboratories International Price Performance

CRL stock opened at $170.70 on Thursday. The firm has a 50 day moving average price of $168.35 and a 200-day moving average price of $185.07. Charles River Laboratories International, Inc. has a 52-week low of $150.79 and a 52-week high of $274.77. The firm has a market capitalization of $8.73 billion, a price-to-earnings ratio of 1,138.01, a PEG ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a quick ratio of 1.14 and a current ratio of 1.41.

Charles River Laboratories International (NYSE:CRL) last announced its quarterly earnings data on Wednesday, February 19th. The medical research company reported $2.66 earnings per share for the quarter, topping analysts’ consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a net margin of 0.52% and a return on equity of 14.69%. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $983.63 million. During the same period in the previous year, the business earned $2.46 EPS. The firm’s revenue for the quarter was down 1.1% on a year-over-year basis. Equities research analysts forecast that Charles River Laboratories International, Inc. will post 9.36 EPS for the current fiscal year.

Insider Buying and Selling

In related news, EVP Joseph W. Laplume sold 4,400 shares of the business’s stock in a transaction that occurred on Thursday, February 20th. The shares were sold at an average price of $162.50, for a total value of $715,000.00. Following the completion of the transaction, the executive vice president now directly owns 20,013 shares in the company, valued at $3,252,112.50. The trade was a 18.02 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO James C. Foster acquired 6,075 shares of the firm’s stock in a transaction that occurred on Thursday, February 20th. The stock was purchased at an average price of $165.01 per share, with a total value of $1,002,435.75. Following the completion of the acquisition, the chief executive officer now owns 183,639 shares in the company, valued at $30,302,271.39. The trade was a 3.42 % increase in their ownership of the stock. The disclosure for this purchase can be found here. 1.30% of the stock is owned by company insiders.

Charles River Laboratories International Company Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).